Methods and compositions for immunizing against pseudomonas infection

Abstract

Methods and compositions for inducing an immune response against Pseudomonas aeruginosa are provided herein. In one aspect, the invention provides a chimeric immunogen, comprising a receptor binding domain, a translocation domain, and a Pseudomonas pilin peptide comprising an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1), wherein the chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses said Pseudomonas pilin peptide to epithelial cells of said subject. In other aspects, the invention provides nucleic acids encoding chimeric immunogens of the invention, kits comprising chimeric immunogens of the invention, cells expressing chimeric immunogens of the invention, and methods of using chimeric immunogens of the invention.

1 . A chimeric immunogen, comprising
 a)—a receptor binding domain,   b)—a translocation domain, and   c)—a  Pseudomonas  pilin peptide comprising an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1),   wherein said chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses said  Pseudomonas  pilin peptide to epithelial cells of said subject.   
     
     
         2 . The chimeric immunogen of  claim 1 , wherein said chimeric immunogen, when administered to said subject, generates an immune response in said subject that reduces the cytotoxicity of  Pseudomonas  exotoxin A to the subject. 
     
     
         3 . The chimeric immunogen of  claim 1 , wherein said chimeric immunogen further comprises an endoplasmic reticulum retention domain. 
     
     
         4 . The chimeric immunogen of  claim 3 , wherein said  Pseudomonas  pilin peptide is located between said translocation domain and said endoplasmic reticulum retention domain. 
     
     
         5 . The chimeric immunogen of  claim 3 , wherein said endoplasmic reticulum retention domain is an enzymatically inactive domain III of  Pseudomonas  exotoxin A. 
     
     
         6 . The chimeric immunogen of  claim 5 , wherein said enzymatically inactive domain III of  Pseudomonas  exotoxin A is inactivated by deleting a glutamate at position 553. 
     
     
         7 . The chimeric immunogen of  claim 3  wherein said endoplasmic reticulum retention domain comprises an amino acid sequence that is selected from the group of RDEL (SEQ ID NO.:2) or KDEL (SEQ ID NO.:3). 
     
     
         8 . The chimeric immunogen of  claim 1 , wherein said translocation domain is selected from the group consisting translocation domains from  Pseudomonas  exotoxin A, diptheria toxin, pertussis toxin, cholera toxin, heat-labile  E. coli  enterotoxin, shiga toxin, and shiga-like toxin. 
     
     
         9 . The chimeric immunogen of  claim 5 , wherein said translocation domain is domain II of  Pseudomonas  exotoxin A. 
     
     
         10 . The chimeric immunogen of  claim 1 , wherein said translocation domain comprises amino acids 280 to 364 of domain II of  Pseudomonas  exotoxin A. 
     
     
         11 . The chimeric immunogen of  claim 1 , wherein said chimeric immunogen comprises more than one of said  Pseudomonas  pilin peptides. 
     
     
         12 . The chimeric immunogen of  claim 1 , wherein said receptor binding domain is selected from the group consisting of domain Ia of  Pseudomonas  exotoxin A; a receptor binding domains from cholera toxin, diptheria toxin, shiga toxin, or shiga-like toxin; a monoclonal antibody, a polyclonal antibody, or a single-chain antibody; TGFα, TGFβ, EGF, PDGF, IGF, or FGF; IL-1, IL-2, IL-3, or IL-6; and MIP-1a, MIP-1b, MCAF, or IL-8. 
     
     
         13 . The chimeric immunogen of  claim 12 , wherein said receptor binding domain is domain Ia of  Pseudomonas  exotoxin A. 
     
     
         14 . The chimeric immunogen of  claim 13 , wherein said domain Ia of  Pseudomonas  exotoxin A has an amino acid sequence that is SEQ ID NO.:4. 
     
     
         15 . The chimeric immunogen of  claim 1 , wherein said receptor binding domain binds to α2-macroglobulin receptor, epidermal growth factor receptor, transferrin receptor, interleukin-2 receptor, interleukin-6 receptor, interleukin-8 receptor, Fc receptor, poly-IgG receptor, asialoglycopolypeptide receptor, CD3, CD4, CD8, chemokine receptor, CD25, CD11B, CD11C, CD80, CD86, TNFα receptor, TOLL receptor, M-CSF receptor, GM-CSF receptor, scavenger receptor, or VEGF receptor. 
     
     
         16 . The chimeric immunogen of  claim 15 , wherein said receptor binding domain binds to α2-macroglobulin receptor. 
     
     
         17 . The chimeric immunogen of  claim 1 , wherein said chimeric immunogen has an amino acid sequence that is SEQ ID NO.:5. 
     
     
         18 . A polynucleotide that encodes a chimeric immunogen, said chimeric immunogen comprising:
 a)—a receptor binding domain,   b)—a translocation domain, and   c)—a  Pseudomonas  pilin peptide that comprises an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1),   wherein said chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses said  Pseudomonas  pilin peptide to epithelial cells of said subject.   
     
     
         19 .- 34 . (canceled) 
     
     
         35 . An expression vector comprising the polynucleotide of  claim 18 . 
     
     
         36 . A cell comprising the expression vector of  claim 35 . 
     
     
         37 . A composition comprising a chimeric immunogen, wherein said chimeric immunogen comprises:
 a)—a receptor binding domain,   b)—a translocation domain, and   c)—a  Pseudomonas  pilin peptide that has an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1)   wherein said chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses said  Pseudomonas  pilin peptide to epithelial cells of said subject.   
     
     
         38 . The composition of  claim 37 , wherein said composition further comprises a pharmaceutically acceptable diluent, excipient, vehicle, or carrier. 
     
     
         39 - 41 . (canceled) 
     
     
         42 . A kit comprising the composition of  claim 37 , wherein said composition is in a single-unit dosage form. 
     
     
         43 . (canceled) 
     
     
         44 . A method for inducing an immune response in a subject, comprising administering to said subject an effective amount of a chimeric immunogen comprising a receptor binding domain, a translocation domain, and a  Pseudomonas  pilin peptide that comprises an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1), wherein said chimeric immunogen induces an immune response in said subject that is effective to reduce adherence of a microorganism expressing the  Pseudomonas  pilin peptide to epithelial cells of said subject when said chimeric immunogen is administered to said subject. 
     
     
         45 - 49 . (canceled) 
     
     
         50 . A method for generating in a subject antibodies specific for a  Pseudomonas  pilin peptide having an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1), comprising administering to said subject an effective amount of a chimeric immunogen comprising a receptor binding domain, a translocation domain, and a  Pseudomonas  pilin peptide that comprises an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1), thereby generating antibodies specific for said  Pseudomonas  pilin peptide. 
     
     
         51 - 54 . (canceled)